At the PAN Foundation Cost-Sharing Roundtable, a variety of voices were represented from across healthcare to discuss the importance of the safety net, explained Daniel J. Klein, president and CEO of the Patient Access Network (PAN) Foundation.
At the PAN Foundation Cost-Sharing Roundtable, a variety of voices were represented from across healthcare to discuss the importance of the safety net, explained Daniel J. Klein, president and CEO of the Patient Access Network (PAN) Foundation.
Transcript
What was a key takeaway from the discussions at the PAN Foundation Cost-Sharing Roundtable?
The roundtable was really pretty energizing, because I think we saw a lot of different perspectives being represented from the payer community, from the pharma community, from the patient advocacy community, from the patient assistance community. And I think my takeaway was that there are some opportunities for common understanding and broadly supported strategies.
I think everybody recognizes that paying for value-based care will free up critical dollars to be used more efficiently to provide patient assistance and I think everybody also came away understanding that the need for a safety net is probably growing. As the patients age, as we go from 57 million patients in Medicare to 70 million plus, it's likely that there's going to be a continuing need for patient assistance, for safety net programs. So it's key that we all work together across our different areas of expertise to make that as efficient as possible, to make sure that it reaches the people who need it, and that everyone can get access to the care they need.
So the roundtable, hopefully, gave everybody a good boost of energy to go back to their offices, to their jobs, to their careers, to their constituents and help move us forward in terms of strenthening and sustaining the safety net.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More